Search Results

Search Results

Research Study Search Results

Return to Search Form
  1. Cancer (Oncology)

    1. Psychoeducation for Spouses of Women with Breast Cancer Frances M. Lewis, PhD, RN, FAAN (University of Washington)
    1. Breast

      1. SWOG 1207: Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer – e3 Breast Cancer Study Gary Goodman, M.D.
      2. SWOG 1202: A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor (AI)-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer Gary Goodman, M.D.
      3. SWOG 1007: A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less Gary Goodman, M.D.
      4. NSABP B-50-I (Katherine): Trastuzumab Emtansine versus Trastuzumab as Adjuvant Therapy for Patients with HER2+ Primary Breast Cancer Who have Residual Tumor Present Pathologically in the Breast or Axillary lymph Nodes Following Preoperative Therapy Tanya Wahl, M.D.
      5. E2112 :A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer Gary Goodman, M.D.
      6. CTSU E2108: A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Christine Lee, M.D.
      7. CRC 14117: Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (METRIC) Erin D. Ellis, MD
      8. CRC 14055: A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer Henry Kaplan, MD
      9. CRC 14034: A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer Erin Ellis, M.D.
      10. CRC 13105: A Randomized Phase 2 Study of Veliparib plus Temozolomide or Veliparib plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects with BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer Erin Ellis, M.D.
      11. CRC 10016: I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2) Erin Ellis, M.D. and Henry Kaplan, M.D.
      12. Combination immunotherapy with Herceptin and the HER2 vaccine E75 in low and intermediate HER2-expressing breast cancer patients to prevent recurrence Henry Kaplan, MD
    2. Cancer Detection Program

      1. Ovarian Cancer Early Detection Program Pamela Paley, M.D.
      2. Flight Attendants Medical Research Institute (FAMRI) – International Early Lung Cancer Action Program (IELCAP) Protocol Ralph Aye, M.D.
    3. Colon

      1. SWOG 0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon Cancer, Phase III Gary Goodman, M.D.
      2. CTSU C80702: A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer Gary Goodman, M.D.
    4. Colorectal

      1. Endometrial

        1. Investigating the Use of Fluorescence Imaging in Endometrial Cancer Surgery Pamela Paley, M.D.
      2. Esophageal

        1. CTSU R1010: A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment Of HER2-Overexpressing Esophageal Adenocarcinoma Gary Goodman, M.D.
      3. Gallbladder or Bile Duct

        1. Kidney

          1. SWOG 0931: EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study Gary Goodman, M.D.
        2. Leukemia

          1. CRC 13084: Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Complete Remission Michael Milder, M.D.
        3. Liver

          1. CRC 13091: A Phase III, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib Philip Gold, M.D.
        4. Lung

          1. SWOG 1206: A Dose Finding Study Followed by Phase II Randomized Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) Gary Goodman, M.D.
          2. SWOG 0905: Randomized Phase II Study of Cediranib (NSC #732208) Versus Placebo in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Malignant Pleural Mesothelioma Gary Goodman, M.D.
          3. CTSU C140503: A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (<=2 cm) Peripheral Non-Small Cell Lung Cancer Gary Goodman, M.D.
          4. CRC 14072: A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC) Howard (Jack) West, M.D.
          5. CRC 14050: An Open Registry to Measure the Impact of Adding RNA Expression Testing on Referral Decisions in Newly Diagnosed Early Stage Lung Adenocarcinoma Patients Eric Vallieres, M.D.
          6. CRC 14035: An Open-label, Phase 1 Dose Escalation Study of Oral ASP8273 in Subjects with Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations Howard (Jack) West, M.D.
          7. CRC 14016: A Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer Stage IIIB, Stage IV or recurrent Howard (Jack) West, M.D.
          8. CRC 14015: Phase 3 Randomized, Placebo-Controlled, Double-blind, Multi-Center, Two-Part Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung) Howard (Jack) West, M.D.
          9. CRC 14014: A Phase 3, Multicenter, Randomized, Open‐Label Cross-Over Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane) as Maintenance Treatment After Induction With Nab-Paclitaxel Plus Carboplatin in Subjects With Squamous Cell NSCLC Howard (Jack) West, M.D.
          10. CRC 14012: Phase II Study of Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib for Patients with EGFR Mutation Who Have Previously Progressed on an EGFR-TKI Howard (Jack) West, M.D.
          11. CRC 13107: Double-Blind, Randomized, Placebo-Controlled Study of Selumetinib in Combination with Docetaxel, in Patients receiving second line treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (SELECT-1) Howard (Jack) West, M.D.
          12. CRC 13086: A Study of Heat Shock Protein 90 (HSP90) Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-Small Cell Lung Cancer (NSCLC) Howard (Jack) West, M.D.
          13. CRC 13049: Open-label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer Who Have Been Treated Previously With Chemotherapy (Platinum Doublet) and Crizotinib Howard (Jack) West, M.D.
          14. A Phase II Multi-Center Study of the Tolerability of Weekly Nab-Paclitaxel as Second Line Treatment for Elderly Patients with Advanced Lung Cancer Howard (Jack) West, M.D.
        5. Multiple Myeloma

          1. CRC 13160: A Placebo-Controlled Study of Oral L-glutamine and Pyridoxal-5-phosphate (Vitamin B6) for the mitigation of Velcade-Induced Peripheral Neuropathy: A Pilot Study Michael Milder, M.D.
          2. CRC 13051: Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Michael Milder, M.D.
        6. Prostate

          1. SWOG 1216: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer Gary Goodman, M.D.
          2. CTSU A031201: Phase III Trial of Enzalutamide versus Enzalutamide Abiraterone and Prednisone For Castration-Resistant Metastatic Prostate Cancer Gary Goodman, MD
        7. Rectal

          1. CTSU N1048: Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision Gary Goodman, M.D.